Clinuvel: positive interim Phase III results for unique skin protection drug
Photoprotective drug afamelanotide moves a step closer to market
26-Jan-2009 -
Melbourne-based Clinuvel Pharmaceuticals Limited achieved positive interim results of its photoprotective drug, afamelanotide, in a Phase III trial conducted in Switzerland. The trial investigated the medical benefits of afamelanotide in the orphan disease erythropoietic protoporphyria (EPP), a ...
density
erythropoietic protoporphyria
food
+8